We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Watson buys Specifar for €400mm to expand into Greece
06 Jun 2011
Executive Summary
Strengthening its position in important European countries, Watson Pharmaceuticals Inc. (generics and branded women’s health products) has acquired private generic drug manufacturer Specifar Pharmaceuticals SA for €400mm ($562mm) in cash. Specifar stockholders may also receive up to €40mm in earn-outs related to the first five years of profits for the company’s generic proton pump inhibitor esomeprazole (AstraZeneca’s Nexium), which is awaiting approval and should be launched later this year in key European markets. The earn-outs will be based on sales in major territories in Europe, Asia, Latin America, and Canada.
Deal Industry
Pharmaceuticals
Pharmaceuticals
Generic Drugs
Deal Status
Final
Deal Type
Acquisition
Full Acquisition
Includes Contract
Includes Earnout
Payment Includes Cash
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?